A nurse in a provider's office is talking with a client who takes oxybutynin. The client asks why he does not urinate as often. Which of the following information should the nurse include about the action of oxybutynin.

The client scenario involves an individual taking a medication for urinary frequency and bladder spasms. To explain its therapeutic mechanism, principles of autonomic pharmacology, competitive antagonism, and detrusor smooth muscle physiology must be applied. Choice A rationale Oxybutynin is an anticholinergic agent that competitively blocks muscarinic M3 receptors on the bladder detrusor muscle. This antagonism inhibits the effects of acetylcholine, preventing involuntary detrusor contractions and effectively increasing bladder capacity and reducing urgency. Choice B rationale Oxybutynin exerts its therapeutic effects specifically on the smooth muscle receptors of the lower urinary tract. It does not affect renal hemodynamics, vascular resistance, or the glomerular filtration rate at which the kidneys process metabolic waste. Choice C rationale Oxybutynin does not alter the central or peripheral nervous system pathways responsible for the production of urine in the nephrons. Urine production remains constant, while the drug alters only the storage and expulsion dynamics within the bladder. Choice D rationale Oxybutynin relaxes the detrusor muscle rather than decreasing the sensitivity of the urethral sphincter. Sphincter relaxation would increase incontinence, whereas oxybutynin reduces frequency by preventing involuntary detrusor contractions while maintaining sphincter tone to store urine..